Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.
Also called NCT07801820
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
- Registry
-
NCT07801820
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07801820. Randomized; double masking; primary purpose treatment. Start 2026-06-23 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- MWN109 1
- Intervention (Drug)
- MWN109 2
- Intervention (Drug)
- MWN109 3
- Intervention (Drug)
- MWN109 4
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Semaglutide Tablets
- Lead sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Record details
- Record id
cardio:ct-nct07801820- Content hash
1bb7f9d13a4a02d2f74ebe7b4647a247fa8e86bf2d73b3881809962ef01c4c3e